Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
December 03, 2018 12:30 ET
|
Helsinn Healthcare S.A.
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting LUGANO,...
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018
November 06, 2018 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018 Lugano, Switzerland, November 6, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products,...
Helsinn Group strengthens the Board with the appointment of Francesco Granata
October 01, 2018 05:05 ET
|
Helsinn Healthcare S.A.
Helsinn Group strengthens the Board with the appointment of Francesco Granata LUGANO, October 1, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products,...
Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S.
June 28, 2018 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S. Iselin, NJ, USA, June 28, 2018 – Helsinn Therapeutics (U.S.) Inc., the U.S. subsidiary of...
The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid
June 26, 2018 11:59 ET
|
Helsinn Healthcare S.A.
The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid Lugano, Switzerland, June 26, 2018 – The United...